echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > AstraZeneca became four strategic cooperation in immunooncology

    AstraZeneca became four strategic cooperation in immunooncology

    • Last Update: 2015-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Biovalley: from April 27, 2015 to April, it seems that the British pharmaceutical giant Azn has begun to exert its influence As of this month, the company has reached four consecutive strategic cooperation in the field of immunooncology, including immunocore, car-t pioneer Juno and celgene The famous biomedical company, innate pharma AstraZeneca's move aims to further tap the clinical potential of immunocheckpoint inhibitor medi4736 (anti PD-L1) The four immunooncology collaborations are as follows: (1) with immunocore, the two sides will cooperate to develop the combination therapy of medi4736 and / or tremelimumab (anti-CTLA-4) and immunotherapy imcgp100 for the potential treatment of melanoma (2) In cooperation with Juno, the two sides will cooperate to develop a combination of medi4736 and car-t therapy targeting CD19 (including jcar014, jacr015 and jacr017) for potential treatment of non Hodgkin's lymphoma (NHL) (3) In cooperation with celgene, AstraZeneca will receive a US $450 million advance payment The two sides will cooperate to develop medi4736 as a single drug therapy or a combination therapy with new potential and existing anticancer drugs, which will be used in the treatment of a wide range of blood tumors, including non Hodgkin's lymphoma (NHL), myelodysplastic syndrome (MDS), multiple myeloma (mm), etc (4) In cooperation with innate Pharma, AstraZeneca will pay a US $250 million advance payment to obtain the exclusive right of innate's immunosuppressive checkpoint inhibitor iph2201 (anti nkg2a) The initial R & D plans of both parties include iph2201 as a single drug therapy for multiple solid tumors, and iph2201 and medi4736 as a combination of immunotherapy for a wide range of tumors; In addition, the two sides will cooperate to develop relevant biomarkers At present, the immunity competition of PD-1 / PD-L1 in the field of pharmaceutical research and development is extremely fierce, with a peak market of US $35 billion Major pharmaceutical giants such as Merck, BMS, Azn and Roche All of them are pushing forward their clinical projects as soon as possible, and at the same time, they have reached extensive cooperation in the field of medicine to investigate the application of single drug and various combination therapies in the treatment of extensive solid tumors and blood tumors In this competition, Bristol Myers and Merck are leading Up to now, opdivo (nivolumab), the blockbuster PD-1 inhibitor, has acquired two indications of melanoma and non-small cell lung cancer (NSCLC) Peyrolizumab, the PD-1 inhibitor of mesardon, has also acquired indications for melanoma Recently, peyrolizumab submitted a listing application to FDA for the treatment of advanced non-small cell lung cancer (NSCLC) However, no indications have been found for AstraZeneca PD-L1 inhibitor medi4736 and Roche PD-L1 inhibitor mpdl3280a About medi4736: medi4736 is a humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) Signals from PD-L1 help tumors escape the immune system Medi4376 can block these signals and resist the immune evasion tactics of tumor It is currently being developed for the treatment of non-small cell lung cancer (NSCLC) and other cancers Medi4736 is also one of the PD-L1 drugs that MedImmune has high hopes for.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.